ClinicalTrials.gg
CompletedNCT00085696Updated Feb 11, 2008

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

A Phase 2 interventional study of VELCADE and rituximab in B-Cell Lymphoma, Follicular Lymphoma and Marginal Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-02-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing bortezomib in Lymphoma, B-Cell — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, B-Cell.

Enrollment
3rd of 12
66 · median 43
Started
2004
the only one that year
Phase 2
7 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
2 of 12
Millennium Pharmaceuticals, Inc.

Among the 12 studies testing bortezomib in Lymphoma, B-Cell, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 7 in phase 2, and was the 3rd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

None of the 12 studies testing bortezomib in Lymphoma, B-Cell is open now. The open studies under Lymphoma, B-Cell, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing bortezomib in Lymphoma, B-Cell as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.

03

Conditions studied

  • B-Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Lymphoma

Keywords

  • Lymphoma
  • Non-Hodgkin's
  • NHL
  • B-Cell
  • Indolent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject 18 years or older
  • Diagnosis of B-cell lymphoma (CD20+) of

    • follicular lymphoma (grades 1, 2, and 3) or
    • marginal zone lymphoma (extranodal, nodal, and splenic)
  • Documented relapse or progression following prior anti-neoplastic treatment.
  • At least 1 measurable lymph node mass that is >1.5 cm.
  • No active CNS lymphoma
  • Voluntary consent

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with VELCADE
  • Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug.
  • Any treatment with nitrosoureas within 6 weeks before the first dose of study drug.
  • Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug.
  • Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug.
  • Radiation therapy within 3 weeks before the first dose of study drug.
  • Major surgery within 2 weeks before the first dose of study drug.
  • Peripheral neuropathy or neuropathic pain
  • History of allergic reaction attributable to compounds containing boron or mannitol
  • Known anaphylaxis or to any component of rituximab
  • Diagnosed or treated for a selected other than NHL within 5 years.
  • Active systemic infection requiring treatment
  • Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study.
  • Male subjects who do not agree to use an acceptable method of for the duration of the study
  • Any serious medical or psychiatric illness likely to interfere with participation in this clinical study
  • Concurrent treatment with another agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants

Interventions

06

Study locations

13 sites
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Emory University Cancer Institute, Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Georgia Cancer Specialists
    Marietta, Georgia 30060, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Midwest Cancer Research Group
    Skokie, Illinois 60077, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Oncology/Henmatology Associates of Kansas City
    Kansas City, Missouri 64111, United States
  • Mid Ohio Oncology/Hematology Inc.
    Columbus, Ohio 43213, United States
  • Charleston Cancer Center
    Charleston, South Carolina 29406, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • FNVHO - US Oncology
    Fairfax, Virginia 20031, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a primary completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2004
First posted
Jun 15, 2004
Start
May 2004
Primary completionActual
Apr 2006
Last update
Feb 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00085696
First posted
Jun 15, 2004
Start date
May 2004
Primary completion
Apr 2006
Last update
Feb 11, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Rituximab

Start the discussion